Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02172690|
Recruitment Status : Unknown
Verified December 2014 by Jiafu Ji, Peking University.
Recruitment status was: Recruiting
First Posted : June 24, 2014
Last Update Posted : December 9, 2014
RATIONALE: Laparoscopic staging may help doctors plan more effective treatment for gastric cancer, yet the efficiency have not been fully investigated in Chinese people.
PURPOSE: Study the effectiveness of laparoscopic staging in patients with pre-diagnosed as locally advanced gastric cancer.
|Condition or disease||Intervention/treatment||Phase|
|Gastric Cancer Peritoneal Metastases||Procedure: Laparoscopic Staging||Not Applicable|
OBJECTIVES: I. Determine the feasibility of laparoscopic staging of patients with pre-diagnosed as locally advanced gastric cancer. II. Assess the adverse effects associated with this technique.
OUTLINE: Surgery. Laparoscopy with cytologic examination.
PROJECTED ACCRUAL: Up to 450 patients will be accrued over approximately 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||450 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Laparoscopic Staging in Patients With Locally Advanced Gastric Cancer in Chinese Patients|
|Study Start Date :||June 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2017|
Experimental: Laparoscopic Staging
For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
Procedure: Laparoscopic Staging
- Peritoneal Metastasis or Positive Cytology [ Time Frame: 7days ]
- Safety [ Time Frame: 30days ]Number of Participants with Adverse Events(III or IV grades according to NCI-CTC)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02172690
|Contact: Jiafu Ji, MDfirstname.lastname@example.org|
|Peking Unicersity Cancer Hospital||Recruiting|
|Beijing, Beijing, China, 100142|
|Contact: Jiafu Ji, MD 86-10-88196391 email@example.com|
|Principal Investigator: Jiafu Ji, MD|
|Principal Investigator:||Jiafu Ji, MD||Peking University|